Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer

被引：0
|
作者：
Arrieta, Oscar [1 ]
Lara-Mejia, Luis [1 ]
Garcia Lopez, Patricia [2 ]
Hernandez-Pedro, Norma [3 ,4 ]
Cruz-Rico, Graciela [1 ]
Heredia, David [1 ]
Sanchez-Reyes, Roberto [1 ]
Infante-Gonzalez, Cesar [1 ]
Martinez Perez, Aida
Matias-Cruz, Venecia [1 ]
Lopez Samchez, Denise [1 ]
Cardona, Andres [5 ]
机构：
[1] Inst Nacl Cancerol, Thorac Oncol Dept, Thorac Oncol Unit, Mexico City, DF, Mexico
[2] Inst Nacl Cancerol, Lab Farmacol, Subdirecc Invest Basica, Mexico City, DF, Mexico
[3] Inst Nacl Cancerol, Thorac Oncol Unit, Mexico City, DF, Mexico
[4] Inst Nacl Cancerol, Lab Personalized Med, Mexico City, DF, Mexico
[5] Clin Country, Clin & Traslat Oncol Grp, Bogota, Colombia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP.01
引用
收藏
页码：S8 / S9
页数：2
相关论文
共 50 条
  • [31] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer (vol 75, pg 75, 2015)
    McKeage, Kate
    DRUGS, 2015, 75 (02) : 241 - 241
  • [32] Sequential Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
    Ito, Kentaro
    Hataji, Osamu
    Kobayashi, Hiroyasu
    Fujiwara, Atsushi
    Yoshida, Masamichi
    D'Alessandro-Gabazza, Corina N.
    Itani, Hidetoshi
    Tanigawa, Motoaki
    Ikeda, Takuya
    Fujiwara, Kentaro
    Fujimoto, Hajime
    Kobayashi, Tetsu
    Gabazza, Esteban C.
    Taguchi, Osamu
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 390 - 396
  • [33] Small-cell transformation o f ALK-rearranged non-small-cell adenocarcinoma of the lung
    Balla, Agnes
    Khan, Farrah
    Hampel, Kenneth J.
    Aisner, Dara L.
    Sidiropoulos, Nikoletta
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2018, 4 (02):
  • [34] Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it
    Drizou, M.
    Kotteas, E. A.
    Syrigos, N.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 658 - 666
  • [35] Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
    Kanaan, Zeyad
    Kloecker, Goetz H.
    Paintal, Ajit
    Perez, Cesar A.
    ONCOTARGETS AND THERAPY, 2015, 8 : 885 - 892
  • [36] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
  • [37] Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib
    Nishino, Mizuki
    Hida, Tomoyuki
    Kravets, Sasha
    Dahlberg, Suzanne E.
    Lydon, Christine A.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Awad, Mark M.
    EUROPEAN JOURNAL OF RADIOLOGY OPEN, 2020, 7
  • [38] Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Mendoza, Dexter P.
    Lin, Jessica J.
    Rooney, Marguerite M.
    Chen, Tianqi
    Sequist, Lecia V.
    Shaw, Alice T.
    Digumarthy, Subba R.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 214 (04) : 766 - 774
  • [39] Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Zhang, Yan
    Wang, Yan
    Li, Junling
    Hao, Xuezhi
    Ma, Di
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S377 - S377
  • [40] Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
    Marianne Oulhen
    Patrycja Pawlikowska
    Tala Tayoun
    Marianna Garonzi
    Genny Buson
    Claudio Forcato
    Nicolò Manaresi
    Agathe Aberlenc
    Laura Mezquita
    Yann Lecluse
    Pernelle Lavaud
    Charles Naltet
    David Planchard
    Benjamin Besse
    Françoise Farace
    npj Precision Oncology, 5
12345